Acceptability. Participants experiencing troublesome adverse effects of any nature · adults with acute affective episodes in bipolar disorder
Topiramate showed no clear difference in acceptability with topiramate (endpoint: 12 weeks) Number of… compared with placebo (low certainty).
1 finding from 1 review
Response to treatment with topiramate. Number of participants experiencing a 50% reduction or greater in mean score from baseline to end of treatment on symptom rating scales in manic and mixed episodes · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
> 50% reduction in depressive symptoms · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) · people with juvenile myoclonic epilepsy
It is very uncertain whether topiramate changes proportion of responders (at least 50% seizure frequency reduction… compared with placebo (very low certainty).
1 finding from 1 review
Proportion of participants who experienced at least one AE and individual AEs · people with juvenile myoclonic epilepsy
1 finding from 1 review
Seizure freedom · people with juvenile myoclonic epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of responders (at least 50% seizure frequency reduction in myoclonic seizures) · people with juvenile myoclonic epilepsy
It is very uncertain whether topiramate changes proportion of responders (at least 50% seizure frequency reduction… compared with valproate (very low certainty).
1 finding from 1 review
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) · people with juvenile myoclonic epilepsy
It is very uncertain whether topiramate changes proportion of responders (at least 50% seizure frequency reduction… compared with valproate (very low certainty).
1 finding from 1 review
Proportion of participants who experienced at least one AE and individual AEs · people with juvenile myoclonic epilepsy
1 finding from 1 review
Seizure freedom · people with juvenile myoclonic epilepsy
It is very uncertain whether topiramate changes number of participants who were seizure‐free compared with valproate (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Topiramate leads to higher 50% or greater reduction in seizure frequency (ITT analysis) compared with placebo (high certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher seizure freedom compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Topiramate leads to higher treatment withdrawal compared with placebo (high certainty).
1 finding from 1 review
Adverse events ‐ weight loss · people with drug‐resistant focal epilepsy
Topiramate may leads to higher adverse effects ‐ weight loss/decrease compared with placebo (low certainty).
1 finding from 1 review
Paraesthesia · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ paraesthesia compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects ‐ 'thinking abnormally' · people with drug‐resistant focal epilepsy
Topiramate leads to higher adverse effects ‐ 'thinking abnormally' compared with placebo (high certainty).
1 finding from 1 review
Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ difficulty with concentration/concentration… compared with placebo (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) All participants ‐ adjusted by seizure type Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with carbamazepine (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate probably leads to higher time to treatment failure (any reason related to treatment)Subgroup:… compared with carbamazepine (moderate certainty).
1 finding from 1 review